Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Cilostazol with Aspirin in Minor Stroke or TIA
NCT06591377Phase 3Recruiting
- Sponsor
- Kafrelsheikh University
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ticagrelor in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Kafrelsheikh University. Primary endpoints: Rate of new stroke at 90 days and Rate of drug hemorrhagic complications at 90 days. Started Aug 2024; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06591377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591377.